Slingshot Biosciences

Slingshot Biosciences announced a leadership change on September 25, 2026. Slingshot Biosciences promoted Chief Operating Officer Dr. Nimisha Srivastava to CEO to lead commercial growth and product development.

What changed

Dr. Nimisha Srivastava was named Chief Executive Officer. Glenn Bilawsky transitioned from the Chief Executive Officer role.

• Leader: Dr. Nimisha Srivastava
• Role: Chief Executive Officer
• Effective: September 23, 2026
• Announcement date: September 25, 2026

Leadership background

Srivastava previously served as Slingshot Biosciences’ Chief Operating Officer. Earlier, she was part of the founding engineering team at Twist Bioscience, where she helped scale laboratory processes, automated workflows, and high-throughput synthetic DNA and RNA production.

The mandate

Slingshot said Srivastava will accelerate commercial growth, advance new product development, strengthen customer relationships, and execute the company’s strategic priorities in precision-engineered cell mimics for flow cytometry.

Why this matters for GTM teams

Executive appointments can precede changes in strategy, operating cadence, hiring, partnerships, and technology priorities. The useful signal is not the title alone: teams should watch the new leader’s stated mandate, prior playbook, organizational scope, and the initiatives announced during the first two quarters.

Source and methodology

This leadership profile is based on the company’s announcement. Roles, transition timing, and biographical details are presented as announced; SalesTools Research does not infer undisclosed succession plans.

Primary source: Slingshot Biosciences leadership announcement.